ECA
DYN icon

Elevate Capital Advisors’s Dyne Therapeutics DYN Stock Holding History

Elevate Capital Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$454K Sell
20,435
-4,165
-17% -$77.4K 0.25% 63
2026
Q1 		$446K Buy
24,600
+486
+2% +$8.38K 0.29% 56
2025
Q4 		$472K Buy
+24,114
New +$457K 0.31% 60

Other funds holding DYN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Elevate Capital Advisors's DYN Position: Q2 2026 in Review

Elevate Capital Advisors reduced its Dyne Therapeutics (DYN) stake by 17% in Q2 2026, selling an estimated $77.4K and leaving 20,435 shares worth $454K. The position accounts for 0.25% of the portfolio, ranked #63.

Elevate Capital Advisors first reported a position in DYN in Q4 2025 and has held it in 3 quarters since. The position peaked at $472K in Q4 2025. 76 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Elevate Capital Advisors held 20,435 shares of Dyne Therapeutics worth $454K as of Q2 2026.
  • Elevate Capital Advisors sold 4,165 Dyne Therapeutics shares in Q2 2026, an estimated $77.4K.
  • Dyne Therapeutics made up 0.25% of Elevate Capital Advisors's portfolio in Q2 2026, its #63 holding.
  • Elevate Capital Advisors first reported a position in Dyne Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Elevate Capital Advisors's Dyne Therapeutics position peaked at $472K in Q4 2025.
  • 76 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Elevate Capital Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.